ClinicalTrials.gg
CompletedNCT00502671Updated Sep 3, 2015Results posted

A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.

A Phase 4 interventional study of capecitabine [Xeloda] in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 46 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-03.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
228
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.

Enrollment
30th of 173
228 · median 55
Started
2007
with 4 others
Phase 4
8 of 179
1 open now
Registered
63rd of 179
by date
Lead sponsor
16 of 179
Hoffmann-La Roche

Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 30th largest by enrollment of the 173 interventional ones that give a count, is one of 5 that started in 2007, is one of 8 in phase 4, and was the 63rd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 24 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies testing capecitabine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This single arm study will evaluate the safety profile of Xeloda as monotherapy for adjuvant treatment of colon cancer. All patients will receive Xeloda 1250mg/m2 p.o. twice daily as intermittent treatment (3 week cycles consisting of 2 weeks of treatment followed by 1 week without treatment). The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • colon cancer (Dukes stage C);
  • surgery, with no evidence of remaining tumor;
  • performance status of \<=1.

Exclusion criteria

Exclusion Criteria:

  • previous therapy for currently treated colon cancer;
  • any evidence of disease;
  • history of other within last 5 years;
  • cardiac disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    1

    Drug: capecitabine [Xeloda]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE

    The postmarketing safety profile of capecitabine was evaluated by collection of AEs, clinical laboratory data, vital signs, and other findings from physical examination. Abnormalities in these findings were captured as AEs, defined as any untoward medical occurrence in a study participant regardless of the suspected cause. Serious AEs were those which, at any dose, met one or more of the following criteria: resulted in fatality, were life-threatening, necessitated new or prolonged existing hospitalization, produced persistent or significant disability, resulted in congenital anomaly or birth defect, were considered medically significant, or required intervention to prevent any of the aforementioned outcomes. Those specific serious AEs which resulted in fatality were also reported separately. The percentage of participants with an AE, serious AE, or AE resulting in death was calculated as \[number of participants with event divided by number analyzed\] multiplied by 100.

    Time frame: Up to 25 weeks (from Baseline to the end of safety follow-up)

Secondary outcomes

  1. Percentage of Participants With Early Withdrawal or Discontinuation Due to an AE

    The postmarketing safety profile of capecitabine was evaluated by collection of AEs, clinical laboratory data, vital signs, and other findings from physical examination. Abnormalities in these findings were captured as AEs, defined as any untoward medical occurrence in a study participant regardless of the suspected cause. The percentage of participants with early withdrawal or treatment discontinuation due to an AE was calculated as \[number of participants with event divided by number analyzed\] multiplied by 100.

    Time frame: Up to 25 weeks (from Baseline to the end of safety follow-up)

07

Results

Posted Sep 3, 2015

Participant flow

Participant flow — Overall Study
MilestoneCapecitabine
Started228
Completed151
Not completed77
Withdrew: Disease progression13
Withdrew: Personal reasons22
Withdrew: Lost to follow-up7
Withdrew: Protocol violation16
Withdrew: Adverse event19

Outcome measures

PrimaryPercentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE

The postmarketing safety profile of capecitabine was evaluated by collection of AEs, clinical laboratory data, vital signs, and other findings from physical examination. Abnormalities in these findings were captured as AEs, defined as any untoward medical occurrence in a study participant regardless of the suspected cause. Serious AEs were those which, at any dose, met one or more of the following criteria: resulted in fatality, were life-threatening, necessitated new or prolonged existing hospitalization, produced persistent or significant disability, resulted in congenital anomaly or birth defect, were considered medically significant, or required intervention to prevent any of the aforementioned outcomes. Those specific serious AEs which resulted in fatality were also reported separately. The percentage of participants with an AE, serious AE, or AE resulting in death was calculated as \[number of participants with event divided by number analyzed\] multiplied by 100.

Time frame:
Up to 25 weeks (from Baseline to the end of safety follow-up)
Reported as:
Number · percentage of participants
Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE
percentage of participantsCapecitabine
Any AE56.1
Serious AE6.1
Death due to an AE0.4
SecondaryPercentage of Participants With Early Withdrawal or Discontinuation Due to an AE

The postmarketing safety profile of capecitabine was evaluated by collection of AEs, clinical laboratory data, vital signs, and other findings from physical examination. Abnormalities in these findings were captured as AEs, defined as any untoward medical occurrence in a study participant regardless of the suspected cause. The percentage of participants with early withdrawal or treatment discontinuation due to an AE was calculated as \[number of participants with event divided by number analyzed\] multiplied by 100.

Time frame:
Up to 25 weeks (from Baseline to the end of safety follow-up)
Reported as:
Number · percentage of participants
Percentage of Participants With Early Withdrawal or Discontinuation Due to an AE
percentage of participantsCapecitabine
Early withdrawal due to an AE8.3
Discontinuation due to an AE10.1

Adverse events

Collected over Up to 25 weeks (from Baseline to the end of safety follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine—14/228 (6.1%)81/228 (35.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventCapecitabine
Myocardial infarctionCardiac disorders2/228
Abdominal abscessGastrointestinal disorders1/228
Colon cancerGastrointestinal disorders1/228
IleusGastrointestinal disorders1/228
Inguinal herniaGastrointestinal disorders1/228
StomatitisGastrointestinal disorders1/228
DeathGeneral disorders1/228
Disease progressionGeneral disorders1/228
CholecystitisHepatobiliary disorders1/228
MetastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/228
Most frequent other events
Most frequent other events
EventCapecitabine
Palmar-plantar erythrodysaesthesia syndromeNervous system disorders48/228
DiarrhoeaGastrointestinal disorders20/228
HyperbilirubinaemiaBlood and lymphatic system disorders17/228
VomitingGastrointestinal disorders12/228

Baseline characteristics

Safety Population: All enrolled participants who received a dose of study medication.

Age, Continuous
Age, Continuous(years)Capecitabine
Mean58 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Capecitabine
Female125
Male103
08

Study locations

46 sites
  • Arkhangelsk, 163045, Russian Federation
  • Astrakhan, 414041, Russian Federation
  • Barnaul, 656049, Russian Federation
  • Belgorod, 308010, Russian Federation
  • Chelyabinsk, 454047, Russian Federation
  • Ekaterinburg, 620905, Russian Federation
  • Irkutsk, 664035, Russian Federation
  • Izhevsk, 426009, Russian Federation
  • Kaluga, 248007, Russian Federation
  • Kazan, 420029, Russian Federation
  • Kazan, 420111, Russian Federation
  • Kirov, 610021, Russian Federation
  • Kostroma, 156005, Russian Federation
  • Krasnodar, 350040, Russian Federation
  • Kursk, 305035, Russian Federation
  • Lipetsk, 398005, Russian Federation
  • Moscow, 105229, Russian Federation
  • Moscow, 107005, Russian Federation
  • Moscow, 119992, Russian Federation
  • Moscow, 123354, Russian Federation
  • Moscow, 127006, Russian Federation
  • Moscow, 143420, Russian Federation
  • Nizhny Novgorod, 603126, Russian Federation
  • Novgorod Veliky, 173016, Russian Federation
  • Obninsk, 249036, Russian Federation
  • Orenburg, 460021, Russian Federation
  • Perm, 614 066, Russian Federation
  • Rostov-na-donu, 344037, Russian Federation
  • Ryazan, 390011, Russian Federation
  • Salekhard, 629001, Russian Federation
  • Samara, 443031, Russian Federation
  • Smolensk, 214000, Russian Federation
  • Soshi, 354057, Russian Federation
  • St Petersburg, 197022, Russian Federation
  • St Petersburg, 197047, Russian Federation
  • Stavropol, 355047, Russian Federation
  • Surgut, 628408, Russian Federation
  • Tollyatti, 445846, Russian Federation
  • Tomsk, 634028, Russian Federation
  • Tomsk, 634050, Russian Federation
  • Tumen, 625047, Russian Federation
  • Tver, 170008, Russian Federation
  • UFA, 450005, Russian Federation
  • UFA, 450054, Russian Federation
  • Volgograd, 400138, Russian Federation
  • Yuzhno-Sakhalinsk, 693010, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2007
First posted
Jul 18, 2007
Start
Jul 2007
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results first posted
Sep 3, 2015
Last update
Sep 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00502671
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 18, 2007
Start date
Jul 2007
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
Sep 3, 2015
Last update
Sep 3, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion